stockrow
Friday 6 November 2026
Export CARL’s income statement to Excel — free account
Carlsmed, Inc.
CARL Healthcare Health Information Services
Carlsmed, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $50.5 million, up 85.9% from fiscal 2024.
- Revenue
- +56.8%
- EPS
- +73.5%
- Free cash flow
- −6.84%
- Total debt
- −0.32%
Quarter to June 2026, against a year earlier
14.42
0.90
−5.87%
Follow CARL
Alert me
| Dec '25 | Dec '24 | |
|---|---|---|
P/E ratio |
0.00 | 0.00 |
Altman Z-Score |
2.94 | — |
P/S ratio |
3.48 | 1.90 |
Altman Z″-Score (non-manufacturers) |
4.88 | (1.45) |
P/FCF ratio |
0.00 | 0.00 |
P/Operating CF |
(33.01) | (9.45) |
Beneish M-Score |
(1.77) | — |
P/B ratio |
1.78 | 0.00 |
Price to Tangible BV |
1.78 | 0.00 |
EV/Sales |
1.61 | 1.39 |
EV/EBITDA |
0.00 | 0.00 |
EV/Operating CF |
(2.80) | (1.79) |
EV/FCF |
(2.67) | (1.74) |
Quick Ratio |
8.49 | 5.33 |
Current Ratio |
8.87 | 5.60 |
Net Debt/EBITDA |
3.12 | 1.03 |
Debt/Assets |
11.79% | 29.74% |
Debt/Equity |
0.16 | 0.60 |
Asset Turnover |
0.56 | 0.00 |
Operating CF/Net income |
0.96 | 1.02 |
Capex/Depreciation |
(4.83) | (1.24) |
Interest Coverage |
(21.38) | (18.26) |
| (214.02%) | 0.00% | |
| (33.22%) | 0.00% | |
ROIC |
(442.13%) | (1,920.54%) |
Return on Tangible Assets |
(26.53%) | (60.91%) |
Average Days of Receivables |
82.10 | 90.91 |
Research and Development Expense of Revenue |
33.69% | 52.66% |
Selling, General and Administrative Expense of Revenue |
102.15% | 109.94% |
Intangible Assets out of Total Assets |
0.00 | 0.00 |
Share Based Compensation of Revenue |
3.82% | 0.93% |
Graham Net Nets |
0.54 | 0.28 |
Graham Number |
0.00 | 0.00 |
Earnings Yield |
(29.64%) | (45.16%) |
Free Cash Flow Yield |
(17.27%) | (41.89%) |
Revenue per Share |
3.55 | 6.68 |
Operating CF per Share |
(2.04) | (6.26) |
Capex per Share |
(0.10) | (0.04) |
Free Cash Flow per Share |
(2.13) | (6.31) |
Cash per Share |
7.73 | 9.89 |
Shareholders Equity per Share |
6.95 | 6.29 |
Interest Debt per Share |
0.00 | 0.00 |
Book value per Share |
6.95 | 6.29 |
Free Cash Flow |
(30.33) | (25.65) |
Working Capital |
112.39 | 40.53 |
Capital Expenditures |
(1.36) | (0.18) |
Net Current Asset Value |
95.42 | 23.12 |
EV/EBIT |
0.00 | 0.00 |
Capex to Sales |
0.03 | 0.01 |
Price to Operating Income |
0.00 | 0.00 |
| Other line items | ||
Depreciation/Fixed assets |
0.19 | 0.56 |
Cash ROIC |
(13.54%) | (31.57%) |
Accounts Receivable Turnover |
5.57 | 0.00 |
Accounts Payable Turnover |
3.62 | 0.00 |
Inventory Turnover |
8.78 | 0.00 |
Average Days of Payables |
131.15 | 123.70 |
Days of Inventory on Hand |
54.00 | 51.03 |
Average Receivables |
9.06 | — |
Average Payables |
3.45 | — |
Average Inventory |
1.42 | — |
Average Assets |
90.97 | — |
Average Common Equity |
14.12 | — |
Columns are period end dates · fundamentals updated 26 Oct 2026